Virtual screening and evaluation of Ketol-Acid Reducto-Isomerase (KARI) as a putative drug target for Aspergillosis

Clinical Proteomics

Eun-ki Kim¹  Shalini Kumari²  Vivek K Morya¹ 

[1] Department of Biological Engineering, Inha University, Incheon, Republic of KoreaDepartment of Biological Engineering, Inha University, Incheon, Republic of KoreaDepartment of Biological Engineering, Inha University, Incheon, Republic of Korea;Department of Biotechnology, H.I.M.T, Greater Noida, IndiaDepartment of Biotechnology, H.I.M.T, Greater Noida, IndiaDepartment of Biotechnology, H.I.M.T, Greater Noida, India

关键词: Aspergillosis;    Aspergillus;    Ketol acid reductoisomerase (KARI);    Pharmacophore;   

DOI  :  10.1186/1559-0275-9-1

来源: Humana Press Inc

【 摘 要 】

Abstract

Aspergillus is a leading causative agent for fungal morbidity and mortality in immuno-compromised patients. To identify a putative target to design or identify new antifungal drug, against Aspergillus is required. In our previous work, we have analyzed the various biochemical pathways, and we found Ketol Acid Reducto-Isomerase (KARI) an enzyme involves in the amino acid biosynthesis, could be a better target. This enzyme was found to be unique by comparing to host proteome through BLASTp analysis. A homology based model of KARI was generated by Swiss model server. The generated model had been validated by PROCHECK and WHAT IF programs. The Zinc library was generated within the limitation of the Lipinski rule of five, for docking study. Based on the dock-score six molecules have been studied for ADME/TOX analysis and subjected for pharmacophore model generation. The Zinc ID of the potential inhibitors is ZINC00720614, ZINC01068126, ZINC0923, ZINC02090678, ZINC00663057 and ZINC02284065 and found to be pharmacologically active agonist and antagonist of KARI. This study is an attempt to Insilco evaluation of the KARI as a drug target and the screened inhibitors could help in the development of the better drug against Aspergillus.

【 授权许可】

Unknown